Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials
- My bad: I left out Fox Chase
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Edward Copeland, surgeon and breast cancer expert, dies at 86